Statement of Changes in Beneficial Ownership (4)
19 December 2020 - 1:24AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Acheson David |
2. Issuer Name and Ticker or Trading Symbol
CHEMBIO DIAGNOSTICS, INC.
[
CEMI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/17/2020 |
(Street)
HAUPPAUGE, NY 11788
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted stock units | (1) | 12/17/2020 | | A | | 14678 | | (2) | (2) | Common stock | 14678 | $0 | 14678 | D | |
Nonqualified stock options | $5.45 | 12/17/2020 | | A | | 23781 | | (3) | 12/16/2027 | Common stock | 23781 | $0 | 23781 | D | |
Explanation of Responses: |
(1) | Each restricted stock unit represents a contingent right to receive one share of Common Stock. |
(2) | The restricted stock units are scheduled to vest in three equal installments on December 17, 2021, 2022 and 2023, provided they shall vest in full immediately prior to a Change in Control (as defined in the 2019 Omnibus Incentive Plan of the issuer). |
(3) | The nonqualified stock options are scheduled to vest and become exercisable in full immediately prior to the earlier to occur of (i) the 2022 annual meeting of stockholders of the issuer and (ii) a Change in Control. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Acheson David C/O CHEMBIO DIAGNOSTICS, INC. 555 WIRELESS BOULEVARD HAUPPAUGE, NY 11788 | X |
|
|
|
Signatures
|
/s/ Mark L. Johnson, Attorney-in-Fact for David Acheson | | 12/18/2020 |
**Signature of Reporting Person | Date |
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2024 to May 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From May 2023 to May 2024